1-4 of 4
Gerd Munzert, MD
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Treatment with AMG 420, an Anti-B-Cell Maturation Antigen (BCMA) Bispecific T-Cell Engager (BiTE ® ) Antibody Construct, Induces Minimal Residual Disease (MRD) Negative Complete Responses in Relapsed and/or Refractory (R/R) Multiple Myeloma (MM) Patients: Results of a First-in-Human (FIH) Phase I Dose Escalation Study

Max S. Topp, Johannes Duell, MD, Gerhard Zugmaier, Michel Attal, Philippe Moreau, Christian Langer, Jan Kroenke, MD, Thierry Facon, Hermann Einsele, Gerd Munzert, MD
Journal: Blood
Blood (2018) 132 (Supplement 1): 1010.
https://doi.org/10.1182/blood-2018-99-109769
Published: 2018
Journal Articles

Phase I/II Study of BI 2536, An Intravenous Polo-Like Kinase-1 (Plk-1) Inhibitor, in Elderly Patients with Relapsed or Refractory Acute Myeloid Leukemia (AML): First Results of a Multi-Center Trial

C. Müller-Tidow, MD, Gesine Bug, MD, Richard Schlenk, MD, Michael Lübbert, MD, PhD, Alwin Krämer, MD, Juergen Krauter, MD, David Nachbaur, MD, Peter Valent, MD, Tillmann Taube, MD, Gerd Munzert, MD, Kang-Hun Lee, MD, Hartmut Dohner, MD
Journal: Blood
Blood (2008) 112 (11): 2973.
https://doi.org/10.1182/blood.V112.11.2973.2973
Published: 2008
Journal Articles

Polo-Like Kinase-1 (Plk-1) Inhibitor BI 2536 Induces Mitotic Arrest and Apoptosis in Vivo: First Demonstration of Target Inhibition in the Bone Marrow of AML Patients

Kang-Hun Lee, MD, Richard F. Schlenk, MD, Gesine Bug, MD, Carsten Müller-Tidow, MD, Ralph M. Waesch, MD, David Nachbaur, MD, Peter Valent, MD, Gerd Munzert, MD, Frank Fleischer, PhD, Hartmut Dohner, MD, PhD, Pilar Garin-Chesa, PhD
Journal: Blood
Blood (2008) 112 (11): 2641.
https://doi.org/10.1182/blood.V112.11.2641.2641
Published: 2008
Journal Articles

Enhanced Anti-Myeloma Activity by Combination of Receptor Tyrosine Kinase (RTK) Inhibition, Proteasome Inhibition, and Dexamethasone: Therapeutic Implications for t(4;14) and t(14;16) Multiple Myeloma (MM) Subgroups.

Guido Bisping, MD, Doris Wenning, Martin H. Kropff, MD, Gerd Munzert, MD, Frank Hilberg, PhD, Gerald J. Roth, PhD, Wolfgang E. Berdel, MD, Joachim Kienast, MD
Journal: Blood
Blood (2005) 106 (11): 112.
https://doi.org/10.1182/blood.V106.11.112.112
Published: 2005